Fennec Announces Positive Results From Phase 3 SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) Presented at the 49th Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

Study met primary endpoint (p=0.0033) Significant reduction in cisplatin induced hearing loss without any evidence of tumour protection in patients with Standard Risk Hepatoblastoma (SR-HB) Company plans to pursue regulatory approvals with FDA and EMA RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX), a specialty pharmaceutical company focused […]

FENNEC TO PRESENT AT THE CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE ON SEPTEMBER 27, 2017 IN NEW YORK CITY

Research Triangle Park, NC, September 20, 2017 – Fennec Pharmaceuticals, Inc. (NASDAQ: FENC, TSX: FRX), today announced that Rosty Raykov, CEO of Fennec, will be presenting at the Cantor Fitzgerald Global Healthcare Conference in New York on September 27 at 4:00 pm. Management will also be available to meet with investors during the conference. The […]

Fennec Announces Preliminary Results of SIOPEL 6 Study on PEDMARK™ (sodium thiosulfate) to be Presented at the 49TH Congress of the International Society of Pediatric Oncology (SIOP) 2017 Meeting

SIOPEL 6 shows that the addition of sodium thiosulfate significantly reduces the incidence of cisplatin-induced hearing loss without any evidence of tumor protection Among the first 94 evaluable patients, hearing loss occurred in 29/44=65.9% under Cisplatin Arm and in 19/50=38.0% under Cis+STS Arm, corresponding to a relative risk of 0.57 (P=0.0069) Late Breaker Oral Presentation […]

Fennec Pharmaceuticals Announces Listing on the Nasdaq Capital Market

Trading on Nasdaq under the symbol “FENC” is expected to commence on September 13, 2017 RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2017 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (TSX:FRX), (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that its […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES SECOND QUARTER 2017 RESULTS

– SIOPEL 6 Results expected Q4 2017 – $7.6 million financing led by VENBIO Select Advisor in June 2017 RESEARCH TRIANGLE PARK, NORTH CAROLINA–(Marketwired – Aug. 11, 2017) – Fennec Pharmaceuticals Inc. (TSX:FRX) (OTCQB:FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported […]

FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

Research Triangle Park, NC — (Marketwired) – June 28, 2017– Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 19, 2017(the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General and Special […]

FENNEC ANNOUNCES $7.6 MILLION PRIVATE PLACEMENT OF COMMON SHARES LED BY VENBIO SELECT ADVISOR

Research Triangle Park, NC, June 8, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) (the “Company” or “Fennec”), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced chemotherapy ototoxicity in pediatric patients, announced today that it has completed a non-brokered private placement (the “Offering”) of 1,900,000 […]

FENNEC ANNOUNCES LAUNCH OF EUROPEAN NAMED PATIENT PROGRAMME FOR SODIUM THIOSULFATE FOR PEDIATRIC PATIENTS WITH STANDARD RISK HEPATOBLASTOMA

Research Triangle Park, NC, May 30, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced the launch of a Named Patient Programme (NPP) in Europe for STS. Fennec’s NPP is intended to […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FIRST QUARTER 2017 RESULTS

Research Triangle Park, NC, May 12, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the first quarter ended March 31, 2017. Upcoming Events for […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES FISCAL YEAR ENDED DECEMBER 31, 2016 FINANCIAL RESULTS

Research Triangle Park, NC, March 30, 2017 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for  the prevention of platinum-induced ototoxicity in pediatric patients, today reported its corporate update and financial results for the year ended December 31, 2016. “We are pleased with […]

FENNEC ANNOUNCES THE LANCET ONCOLOGY PUBLICATION OF CHILDREN’S ONCOLOGY GROUP STUDY OF SODIUM THIOSULFATE

Research Triangle Park, NC, December 1, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced The Lancet Oncology published the results from the Children’s Oncology Group, “Effects of Sodium Thiosulfate versus Observation […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES THIRD QUARTER 2016 RESULTS

SIOPEL 6 Updated Interim Results Presented at the International Society of Pediatric Oncology (SIOP) -confirms no evidence of tumor protection and final audiometry results will be available in the fourth quarter of 2017 Research Triangle Park, NC, November 14, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the […]

FENNEC ANNOUNCES UPDATE OF SIOPEL 6 STUDY ON SODIUM THIOSULFATE (STS) PRESENTED AT THE INTERNATIONAL SOCIETY OF PAEDIATRIC ONCOLOGY (SIOP) 2016 MEETING

No difference in Event free Survival (EFS) and Overall Survival (OS) at 2 years for cisplatin alone vs cisplatin + STS with no evidence of tumor protection  Final audiometry results will be available at the end of 2017 Research Triangle Park, NC, October 24, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty […]

FENNEC TO PRESENT AT RODMAN & RENSHAW 18TH ANNUAL GLOBAL INVESTMENT CONFERENCE IN NEW YORK ON SEPTEMBER 13, 2016

Research Triangle Park, NC, September 8, 2016 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that Rosty Raykov, CEO of Fennec, will present at the Rodman & Renshaw 18th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The Company will be presenting at 3:25 EDT on Tuesday, September 13, 2016. […]

FENNEC PROVIDES CORPORATE UPDATE AND ANNOUNCES SECOND QUARTER 2016 RESULTS

SIOPEL 6 interim results presented in oral presentation at ASCO 2016 confirms no evidence of tumor protection and is consistent with previous updates. Initial hearing efficacy data are “encouraging” with final hearing results expected in H2 2017. Closing of $5.0 million financing by Essetifin SpA (formerly Sigma Tau Finanziaria SpA) provides sufficient reserves to complete […]

FENNEC ANNOUNCES APPOINTMENT OF MARCO BRUGHERA TO THE BOARD OF DIRECTORS

Research Triangle Park, NC, August 11, 2016 – Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF), a specialty pharmaceutical company focused on the development of Sodium Thiosulfate (STS) for the prevention of platinum-induced ototoxicity in pediatric patients, announced today the appointment of Marco Brughera, DVM, CEO and Global Head of Sigma Tau Rare Disease, to its […]

FENNEC TO PRESENT AT CANTOR FITZGERALD’s 2nd ANNUAL HEALTHCARE CONFERENCE IN NEW YORK ON JULY 13, 2016

Research Triangle Park, NC, July 6, 2016 – Fennec Pharmaceuticals, Inc. (TSX: FRX, OTCQB: FENCF), today announced that the Company will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference in New York City at 10:45 AM EDT on Wednesday, July 13, 2016. The conference is being held at the Le Parker Meridian in New […]

Fennec Announces Results of Annual Meeting

Research Triangle Park, NC — (Marketwired) – June 8, 2016– Fennec Pharmaceuticals Inc. (TSX: FRX, OTCQB: FENCF) today announced that the nominees listed in the management proxy circular dated May 9, 2016 (the “Circular”) for the Annual Meeting of Shareholders were elected as directors of the Company at the Annual Meeting of Shareholders held in […]